<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="application/xml; charset=UTF-8">
<title>input-it</title>
</head>
<body><div id="lawcontent">
<div id="preface">
<!--531.80 --><p class="srnummer">531.80 </p>
<h1 class="erlasstitel botschafttitel">Ordinanza<br>sul centro di notifica per i medicamenti per uso umano d’importanza vitale</h1>
<p class="erlassdatum man-space-before-3">del 28 maggio 2025 (Stato 1° luglio 2025)</p>
</div>
<div id="preamble"><div>
<p class="man-template-autor man-space-before-10">Il Consiglio federale svizzero,</p>
<p class="ingress man-space-before-3">visto l’articolo 57 capoverso 1 della legge del 17 giugno 2016<sup><a href="#fn-d7e19" id="fnbck-d7e19">1</a></sup> sull’approvvigionamento del Paese,</p>
<p class="man-template-verb man-space-before-3 man-space-after-18">ordina:</p>
<div class="footnotes"><p id="fn-d7e19"><sup><a href="#fnbck-d7e19">1</a></sup><sup></sup> <a href="https://fedlex.data.admin.ch/vocabulary/legal-taxonomy/7641" target="_blank" data-rs-uri="https://fedlex.data.admin.ch/eli/cc/2017/308" data-rs="531" data-lang="it">RS <b>531</b></a></p></div>
</div></div>
<main id="maintext"><section id="sec_1"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_1">Sezione 1:  Centro di notifica</a>
</h1>
<div class="collapseable"><article id="art_1"><a name="a1"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_1"><b>Art. 1</b></a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Il settore specializzato Agenti terapeutici dell’organizzazione dell’approvvigionamento economico del Paese gestisce un centro di notifica per garantire l’approvvigionamento del Paese con medicamenti per uso umano d’importanza vitale.</p>
<p class="absatz man-space-before-4"><sup>2</sup> Sono considerati d’importanza vitale i medicamenti per uso umano omologati dall’Istituto svizzero per gli agenti terapeutici:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">non sostituibili o sostituibili solo in parte; e</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">la cui carenza per un lungo periodo causerebbe gravi conseguenze per la salute.</dd>
</dl>
</div></article></div></section><section id="sec_2"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_2">Sezione 2:  Notifica</a>
</h1>
<div class="collapseable">
<article id="art_2"><a name="a2"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_2"><b>Art. 2</b> Obbligo di notifica </a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> I titolari dell’omologazione di un medicamento per uso umano contenente uno dei principi attivi di cui all’allegato devono notificare al centro di notifica le difficoltà di approvvigionamento o le interruzioni delle forniture prevedibili e non prevedibili per i medicamenti per uso umano d’importanza vitale se la durata di tali difficoltà o interruzioni è presumibilmente superiore a 14 giorni. </p>
<p class="absatz man-space-before-4"><sup>2</sup> Devono notificare quale dosaggio di una forma galenica è interessato e quando si presume che sarà nuovamente disponibile.</p>
<p class="absatz man-space-before-4"><sup>3</sup> Le difficoltà di approvvigionamento o l’interruzione delle forniture non devono essere notificate se concernono soltanto le confezioni di una certa grandezza di un determinato dosaggio di una forma galenica sostituibili con confezioni di un’altra grandezza.</p>
<p class="absatz man-space-before-4"><sup>4</sup> Le notifiche devono essere effettuate entro cinque giorni lavorativi a decorrere dal giorno in cui il titolare dell’omologazione viene a conoscenza della difficoltà di approvvigionamento o dell’interruzione delle forniture.</p>
</div></article><article id="art_3"><a name="a3"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_3"><b>Art. 3</b> Contenuto e forma della notifica</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Il titolare dell’omologazione deve notificare in particolare quanto segue:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">il nome e indirizzo nonché una persona di riferimento;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">il numero di omologazione e il codice di articolo del medicamento per uso umano;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">la denominazione esatta del medicamento per uso umano, inclusi il principio attivo, la forma galenica, il dosaggio e la grandezza della confezione;</dd>
<dt class="man-space-before-4">d. </dt>
<dd class="man-space-before-4">la situazione, incluse le cause, le sedi coinvolte in Svizzera e all’estero, la disponibilità di scorte, le vendite effettuate e quelle previste;</dd>
<dt class="man-space-before-4">e. </dt>
<dd class="man-space-before-4">l’indicazione di un’eventuale alternativa equivalente, disponibile in Svizzera o all’estero;</dd>
<dt class="man-space-before-4">f. </dt>
<dd class="man-space-before-4">l’inizio, la durata e l’entità della difficoltà di approvvigionamento o dell’interruzione delle forniture;</dd>
<dt class="man-space-before-4">g. </dt>
<dd class="man-space-before-4">le misure adottate o previste per rispondere alla difficoltà di approvvigionamento o all’interruzione delle forniture.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> La notifica deve essere effettuata tramite il sistema d’informazione del centro di notifica (Piattaforma degli agenti terapeutici). Se per motivi tecnici non è possibile utilizzare la Piattaforma degli agenti terapeutici, i dati sono inviati tramite un altro canale elettronico o per posta. </p>
</div></article><article id="art_4"><a name="a4"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_4"><b>Art. 4</b> Segnalazione di difficoltà di approvvigionamento e di interruzioni delle forniture</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Cantoni, ospedali, medici, farmacisti e grossisti possono segnalare al centro di notifica un’eventuale difficoltà di approvvigionamento o interruzione delle forniture. </p></div></article>
</div></section><section id="sec_3"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_3">Sezione 3:  Informazione e raccomandazioni</a>
</h1>
<div class="collapseable">
<article id="art_5"><a name="a5"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_5"><b>Art. 5</b> Informazione delle autorità sanitarie e dei fornitori di prestazioni</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> Il centro di notifica verifica le notifiche e informa in merito alle difficoltà di approvvigionamento e all’interruzione delle forniture le autorità sanitarie dei Cantoni e della Confederazione nonché i fornitori di prestazioni riportati di seguito:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">i medici;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">i farmacisti;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">le levatrici;</dd>
<dt class="man-space-before-4">d. </dt>
<dd class="man-space-before-4">le persone dispensanti cure previa prescrizione o indicazione medica e le organizzazioni che le occupano;</dd>
<dt class="man-space-before-4">e. </dt>
<dd class="man-space-before-4">gli ospedali;</dd>
<dt class="man-space-before-4">f. </dt>
<dd class="man-space-before-4">le case per partorienti;</dd>
<dt class="man-space-before-4">g. </dt>
<dd class="man-space-before-4">le case di cura;</dd>
<dt class="man-space-before-4">h. </dt>
<dd class="man-space-before-4">gli istituti che dispensano cure ambulatoriali effettuate da medici.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> Il settore specializzato Agenti terapeutici informa le autorità sanitarie dei Cantoni e della Confederazione nonché i fornitori di prestazioni interessati in merito a principi attivi alternativi ed eventuali possibilità di sostituzione.</p>
<p class="absatz man-space-before-4"><sup>3</sup> In caso di segnalazione secondo l’articolo 4, il titolare dell’omologazione deve aver confermato la difficoltà di approvvigionamento o l’interruzione delle forniture prima che il centro di notifica informi in merito.</p>
</div></article><article id="art_6"><a name="a6"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_6"><b>Art. 6</b> Raccomandazioni</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Se un medicamento per uso umano è soggetto all’obbligo di notifica, il settore specializzato Agenti terapeutici emana raccomandazioni:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">sulla limitazione d’impiego di medicamenti per uso umano in presenza di determinate indicazioni o per determinate categorie di pazienti;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">sull’importazione di medicamenti per uso umano non omologati in Svizzera da un Paese in cui vige un controllo degli agenti terapeutici equivalente;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">sull’approvazione delle domande dei titolari di omologazioni in merito all’immissione in commercio temporanea di medicamenti per uso umano identici in confezione estera.</dd>
</dl>
</div></article>
</div></section><section id="sec_4"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_4">Sezione 4:  Protezione dei dati</a>
</h1>
<div class="collapseable">
<article id="art_7"><a name="a7"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_7"><b>Art. 7</b> Accesso alla Piattaforma degli agenti terapeutici</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Hanno accesso alla Piattaforma degli agenti terapeutici:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">i collaboratori del centro di notifica;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">i consulenti in materia di protezione dei dati dell’Ufficio federale per l’approvvigionamento economico del Paese ai fini dell’adempimento della loro funzione di controllo;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">le persone responsabili del funzionamento e della manutenzione del sistema.</dd>
</dl>
</div></article><article id="art_8"><a name="a8"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_8"><b>Art. 8</b> Principi della comunicazione dei dati</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4"><sup>1</sup> I dati della Piattaforma degli agenti terapeutici possono essere comunicati esclusivamente:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">alle autorità sanitarie di un Cantone o della Confederazione per l’adempimento dei relativi mandati legali;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">a terzi, se li impiegano esclusivamente a scopi scientifici.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> Prima di comunicare i dati secondo il capoverso 1 lettera b, il centro di notifica li rende anonimi e assicura che non permettano di risalire a segreti d’affari o di fabbricazione.</p>
<p class="absatz man-space-before-4"><sup>3</sup> I destinatari dei dati adottano le misure organizzative e tecniche necessarie a garantire che i dati siano utilizzati esclusivamente per lo scopo indicato. La trasmissione dei dati può avvenire solo previo consenso del centro di notifica.</p>
</div></article><article id="art_9"><a name="a9"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_9"><b>Art. 9</b> Comunicazione dei dati all’Istituto svizzero per gli agenti terapeutici</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Mediante procedura di richiamo il centro di notifica comunica ai collaboratori dell’Istituto svizzero per gli agenti terapeutici i seguenti dati necessari per l’elaborazione delle richieste secondo l’articolo 9<i>b</i> capoverso 2 della legge del 15 dicembre 2000<sup><a href="#fn-d7e277" id="fnbck-d7e277">2</a></sup> sugli agenti terapeutici (LAter):</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">dati relativi alle difficoltà di approvvigionamento e interruzioni delle forniture di medicamenti per uso umano d’importanza vitale soggetti all’obbligo di notifica;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">valutazioni e raccomandazioni del settore specializzato Agenti terapeutici concernenti la situazione dell’approvvigionamento;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">informazioni sulle possibilità di sostituzione.</dd>
</dl>
<div class="footnotes"><p id="fn-d7e277"><sup><a href="#fnbck-d7e277">2</a></sup><sup></sup> <a href="https://fedlex.data.admin.ch/vocabulary/legal-taxonomy/9354" target="_blank" data-rs-uri="https://fedlex.data.admin.ch/eli/cc/2001/422" data-rs="812.21" data-lang="it">RS <b>812.21</b></a></p></div>
</div></article><article id="art_10"><a name="a10"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_10"><b>Art. 10</b> Comunicazione dei dati a Helvecura</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">Mediante procedura di richiamo il centro di notifica comunica ai collaboratori dell’organizzazione di mutua assistenza dei detentori di scorte obbligatorie di agenti terapeutici (Helvecura) i seguenti dati necessari all’adempimento dei compiti loro affidati in relazione alla costituzione di scorte obbligatorie:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">dati relativi alle forniture e alle vendite dei medicamenti per uso umano registrati nella Piattaforma degli agenti terapeutici;</dd>
<dt class="man-space-before-4">b. </dt>
<dd class="man-space-before-4">dati di contatto della persona di riferimento;</dd>
<dt class="man-space-before-4">c. </dt>
<dd class="man-space-before-4">dati statistici.</dd>
</dl>
</div></article><article id="art_11"><a name="a11"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_11"><b>Art. 11</b> Comunicazione dei dati da parte di Refdata e Helvecura</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4" msg:wcstyle02-4="loose pPr/keepLines" xmlns:msg="urn:com:c-moria:legi4ch:xslt:message"><sup>1</sup> Mediante procedura di richiamo i seguenti organi comunicano al centro di notifica i dati sotto riportati:</p>
<dl class="man-space-after-0">
<dt class="man-space-before-4">a. </dt>
<dd class="man-space-before-4">l’istituzione di cui all’articolo 67 capoverso 3 LATer<sup><a href="#fn-d7e343" id="fnbck-d7e343">3</a></sup> (Refdata): tutti i dati dell’istituzione;</dd>
<dt class="man-space-before-4">b.  </dt>
<dd class="man-space-before-4">Helvecura: i dati relativi allo stato attuale e allo stato auspicato delle scorte nonché alle vendite dei medicamenti per uso umano registrati nella Piattaforma degli agenti terapeutici.</dd>
</dl>
<p class="absatz man-space-before-4"><sup>2</sup> Il centro di notifica può richiamare tali dati soltanto se ne ha bisogno per adempiere il suo mandato legale, in particolare per adottare le misure preparatorie e d’intervento necessarie.</p>
<div class="footnotes"><p id="fn-d7e343"><sup><a href="#fnbck-d7e343">3</a></sup><sup></sup> <a href="https://fedlex.data.admin.ch/vocabulary/legal-taxonomy/9354" target="_blank" data-rs-uri="https://fedlex.data.admin.ch/eli/cc/2001/422" data-rs="812.21" data-lang="it">RS <b>812.21</b></a></p></div>
</div></article><article id="art_12"><a name="a12"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_12"><b>Art. 12</b><b></b> <b></b>Durata di conservazione</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">I dati registrati nella Piattaforma degli agenti terapeutici vengono conservati per almeno dieci anni a decorrere dalla loro registrazione e cancellati al più tardi 15 anni dopo la loro registrazione.</p></div></article><article id="art_13"><a name="a13"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_13"><b>Art. 13</b><b></b> <b></b>Sicurezza dei dati</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Il settore specializzato Agenti terapeutici disciplina in un apposito regolamento le misure organizzative e tecniche per impedire il trattamento non autorizzato dei dati e per garantire la verbalizzazione automatica del trattamento dei dati.</p></div></article>
</div></section><section id="sec_5"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_5">Sezione 5:  Finanziamento</a>
</h1>
<div class="collapseable"><article id="art_14"><a name="a14"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_14"><b>Art. 14</b></a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Il centro di notifica è finanziato dalla Confederazione. </p></div></article></div></section><section id="sec_6"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#sec_6">Sezione 6:  Disposizioni finali</a>
</h1>
<div class="collapseable">
<article id="art_15"><a name="a15"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_15"><b>Art. 15</b><b></b> <b></b>Esecuzione</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Il settore specializzato Agenti terapeutici esegue la presente ordinanza.</p></div></article><article id="art_16"><a name="a16"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_16"><b>Art. 16</b> Modifica dell’allegato</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">Il Dipartimento federale dell’economia, della formazione e della ricerca può modificare l’allegato previa consultazione dei Cantoni, delle cerchie economiche interessate e delle organizzazioni del settore sanitario.</p></div></article><article id="art_17"><a name="a17"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_17"><b>Art. 17</b> Abrogazione di altri atti normativi</a>
</h6>
<div class="collapseable">
<p class="absatz man-space-before-4">L’ordinanza del 12 agosto 2015<sup><a href="#fn-d7e422" id="fnbck-d7e422">4</a></sup> sul centro di notifica per i medicamenti a uso umano d’importanza vitale è abrogata.</p>
<div class="footnotes"><p id="fn-d7e422"><sup><a href="#fnbck-d7e422">4</a></sup><sup></sup> [<a href="https://fedlex.data.admin.ch/eli/oc/2015/544" target="_blank">RU <b>2015</b> 2895</a>; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2017/313" target="_blank"><b>2017</b> 3179 </a>cifra I n. 1; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2021/132" target="_blank"><b>2021</b> 132 </a>all. n. 29; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2022/568" target="_blank"><b>2022 </b>568 </a>all. 2  cifra II n. 67; <b></b><a href="https://fedlex.data.admin.ch/eli/oc/2023/735" target="_blank"><b>2023</b> 735 </a>all. 2 cifra II n. 33, <a href="https://fedlex.data.admin.ch/eli/oc/2023/802" target="_blank">802</a>]</p></div>
</div></article><article id="art_18"><a name="a18"></a><h6 class="heading" role="heading">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#art_18"><b>Art. 18</b> Entrata in vigore</a>
</h6>
<div class="collapseable"><p class="absatz man-space-before-4">La presente ordinanza entra in vigore il 1° luglio 2025.</p></div></article>
</div></section></main><div id="annex"><section id="annex_u1"><h1 class="heading" role="heading" aria-level="1">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_u1">Allegato</a>
</h1>
<div class="collapseable">
<p class="titelanhtext">(art. 2 cpv. 1)</p>
<section id="annex_u1/lvl_u1"><h2 class="heading" role="heading" aria-level="2">
<span class="display-icon"></span><span class="external-link-icon"></span><a href="#annex_u1/lvl_u1">Lista dei principi attivi</a>
</h2>
<div class="collapseable">
<p></p>
<div class="table"><table border="1">
			
			
			<tr>
				
				
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Codice ATC*</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Principio attivo</p>
				</th>
				<th class="man-text-align-left">
					
					<p class="man-template-tab-kpf man-space-before-3 man-space-after-3">Osservazioni</p>
				</th>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A07A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antinfettivi intestinali</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A09AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">polienzimi (lipasi, proteasi, ecc.)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A10A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">insuline e analoghi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11CC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">colecalciferolo (vitamina D3)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11DA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tiamina (vitamina B1)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11DB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vitamina B1 in combinazione con vitamina B6 e/o vitamina B12</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11GA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acido ascorbico (vitamina C)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11HA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">piridossina (vitamina B6)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A11HA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">riboflavina (vitamina B2)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A12CC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">magnesio solfato</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">A12CE02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">selenito di sodio</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fenprocumone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AA07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acenocumarolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB01 </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">eparina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">&gt; 100 IE/ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antitrombina III</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dalteparina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">enoxaparina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">nadroparina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AB09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">danaproid</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AD02 </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">alteplasi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dosaggio &gt; 2 mg</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AD04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">urochinasi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AD11</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tenecteplase</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AE03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">argatroban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AE07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dabigatran</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AF01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">rivaroxaban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AF02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">apixaban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">edoxaban</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B01AX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fondaparinux</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B02AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acido tranexamico</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B02BD</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fattori della coagulazione del sangue </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">albumina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">aminoacidi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">emulsioni di grassi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carboidrati</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali con una concentrazione di glucosio ≥ 20 % w/V, volume &gt; 50 ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BA10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">soluzioni nutrizionali parenterali, combinazioni</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">per sistemi con sacca a tre compartimenti e catetere venoso centrale</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05BB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">soluzioni di elettroliti</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05DB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">soluzioni ipertoniche per dialisi peritoneale </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XA14</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sodio glicerofosfato</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XA31</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">elettroliti in combinazione con altri farmaci, incl. microelementi allo stato puro</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">alanilglutamina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05XC</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vitamine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">B05ZB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">emofiltrati</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">isoprenalina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">noradrenalina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dobutamina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C01CA24</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">adrenalina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C03CA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">furosemide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C07AB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">metoprololo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">C07AG01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">labetalolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AC52</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">clorexidina, combinazioni</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">volume &gt; 100 ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AG02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">povidone-iodio</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">volume &gt; 100 ml</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AJ57 </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">octenidina, combinazioni</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">isopropanolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">D08AX53</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">propanolo, combinazioni</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">G02AD05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sulprostone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01AA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tetracosactide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01BA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">desmopressina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ossitocina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">H01BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carbetocina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antibiotici per uso sistemico</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">senza J01Z</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">antimicotici per uso sistemico</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J04A</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">medicamenti per il trattamento della tubercolosi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AB06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ganciclovir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AB14</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">valganciclovir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">foscarnet</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J05AH02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">oseltamivir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline umane</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">normali, per somministrazione extravascolare</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline umane</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">normali, per somministrazione intravascolare</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobuline anti-D</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobulina antitetanica</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobulina antivaricella/zoster</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobulina antiepatite B</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J06BB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobulina antirabica</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">J07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vaccini</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ciclofosfamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">melfalan</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ifosfamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AA09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bendamustina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">busulfano</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tiotepa</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carmustina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">temozolomide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01AX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dacarbazina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">metotressato</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mercaptopurina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tioguanina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cladribina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fludarabina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BB07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">nelarabina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">citarabina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fluorouracile</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">gemcitabina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">capecitabina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01BC07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">azacitidina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vincristina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vinorelbina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">etoposide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">paclitaxel</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CD02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">docetaxel</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CD04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cabazitaxel</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CE02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">irinotecano</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vecchio codice ATC: L01XX19</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01CX01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trabectedina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01DB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">doxorubicina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01DB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">epirubicina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01DC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bleomicina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">imatinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">osimertinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dabrafenib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trametinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EH02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">neratinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EL01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ibrutinib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vandetanib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01EX10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">midostaurina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">rituximab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">inotuzumab ozogamicina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FC01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">daratumumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FD01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trastuzumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FD02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pertuzumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FD03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">trastuzumab emtansine</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cetuximab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FF02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pembrolizumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">durvalumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FF05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">atezolizumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FG01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bevacizumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FG02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ramucirumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">gemtuzumab ozogamicina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ipilimumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">brentuximab vedotin</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01FX07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">blinatumomab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cisplatino</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XA02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carboplatino</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">oxaliplatino</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XF01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tretinoina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XG01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">bortezomib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XG02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">carfilzomib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XH03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">panobinostat</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XJ01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vismodegib</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">idroxicarbamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX23</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mitotano</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX24</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pegaspargasi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX27</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">arsenico triossido</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L01XX52</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">venetoclax</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L02AE03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">goserelin</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L02BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tamoxifene</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L02BA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fulvestrant</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L03AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">vaccino BCG</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AA04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">immunoglobulina antimonocitaria (coniglio)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AA13</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">leflunomide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AB06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">golimumab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">basiliximab</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AX01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">azatioprina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme perorali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">metotrexato</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme perorali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">L04AX04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lenalidomide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M01AB05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">diclofenac</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M01AB15</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ketorolac</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M01AE17</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dexketoprofene</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AB01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">suxamethonium</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AC04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">atracurio</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AC09</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">rocuronio</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03AC11</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">cisatracurio</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">M03CA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">dantrolene</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AB07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">desflurano</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">thiopental</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AH</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">anenestetici oppiodi</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AH06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">remifentanil</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AX03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ketamina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01AX10</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">propofol</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lidocaina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01BB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mepivacaina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N01BB04</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">prilocaina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">morfina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">idromorfone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ossicodone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA08</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">diidrocodeina </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">senza antitussivi</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AA55</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ossicodone e naloxone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">petidina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AB03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fentanile</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">buprenorfina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AF02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">nalbufina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AJ06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">codeina con paracetamolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AJ13</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tramadolo con paracetamolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AX01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tilidina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AX02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tramadolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02AX06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">tapentadolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">acido acetilsalicilico, incl. acetilsalicilato di lisina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02BB02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">metamizolo sodico</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N02BE01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">paracetamolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N03AX18</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lacosamide</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N05BA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">diazepam</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali e gocce</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N05BA06</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lorazepam</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N07BC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">metadone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">N07BC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">levometadone</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">R03CC02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">salbutamolo</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">forme parenterali</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">R03CC05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">exoprenalina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">S01AD03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">aciclovir</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">pomata oftalmica</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">S01JA01</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">fluorescina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">collirio</p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AB14</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">protamina</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AB35</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sugammadex</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE02</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">sevelamer</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">lantanio carbonato</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE05</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">ossidrossido sucroferrico</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AE07</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">calcio acetato </p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V03AF03</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">calcio folinato (acido folinico)</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08AA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mezzi di contrasto radiologici, idrosolubili, nefrotropici, ad alta osmolarità</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08AB</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mezzi di contrasto radiologici, idrosolubili, nefrotropici, a bassa osmolarità</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08BA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mezzi di contrasto radiologici contenenti solfato di bario</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">V08CA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3">mezzi di contrasto paramagnetici</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-before-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">V08DA</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3">mezzi di contrasto per ultrasonologia</p>
				</td>
				<td>
					
					<p class="man-template-tab-krpr man-space-after-3"></p>
				</td>
			</tr>
			<tr>
				
				
				<td colspan="3"><dl class="man-space-after-0">
<dt class="man-space-after-3">* </dt>
<dd class="man-space-after-3">Il codice ATC (codice del principio attivo secondo <i>l’Anatomical Therapeutic Chemical Classification System</i>) può essere consultato nella versione ufficiale inglese sul sito del <i>Collaborating Centre for Drug Statistics Methodology</i> dell’Organizzazione mondiale della sanità (OMS) all’indirizzo seguente: <a href="https://www.whocc.no/atc_ddd_index/" target="_blank">
							www.whocc.no
						</a> &gt; ATC/DDD Index. I prodotti sono catalogati secondo la classificazione ATC dell'Istituto svizzero per gli agenti terapeutici.</dd>
</dl></td>
			</tr>
		</table></div>
<p class="abstand1seite man-space-before-0"></p>
</div></section>
</div></section></div>
</div></body>
</html>
